Sensus Healthcare (SRTS) Scheduled to Post Quarterly Earnings on Thursday

Posted by Defense World Staff on Nov 7th, 2024

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Thursday, November 14th. Analysts expect the company to post earnings of ($0.02) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.07. Sensus Healthcare had a return on equity of 13.46% and a net margin of 18.27%. The business had revenue of $9.24 million for the quarter, compared to analyst estimates of $7.00 million. During the same period in the prior year, the company earned ($0.02) EPS. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $6.69 on Thursday. The company has a market cap of $109.65 million, a price-to-earnings ratio of 16.32 and a beta of 1.04. The stock has a fifty day moving average price of $6.26 and a two-hundred day moving average price of $5.77. Sensus Healthcare has a 52-week low of $1.79 and a 52-week high of $7.18.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Roth Capital raised Sensus Healthcare to a “strong-buy” rating in a report on Friday, July 12th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Sensus Healthcare in a research report on Monday, August 12th.

Check Out Our Latest Stock Analysis on Sensus Healthcare

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.